Skip to main content

Conference Coverage

American Society of Clinical Oncology Genitourinary Cancers Symposium


J Clin Pathways. 2018;4(2):17-20.

Photo Courtesy of ASCO/Todd Buchanan 2018

The 2018 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium provides a forum for physicians and other members of the oncology care and research community who diagnose, treat, and study genitourinary malignancies. Attendees gather at this annual meeting to hear the latest science in an array of areas, including prostate, renal, urothelial, testicular, and adrenal cancers, and how it can be applied in clinical settings.

The 2018 theme for the Symposium was “Translating Evidence to Multidisciplinary Care” and focused on giving health care providers across multiple disciplines and professions the opportunity to connect and discuss the newest research and recommendations for improving care for patients with GU cancers. New diagnostic approaches and therapy options are being innovated and implemented using multidisciplinary precision care and may provide a way forward in the effort to reduce rates of incidence and mortality in this population.

Journal of Clinical Pathways covered topics related to value-based care strategies and comparative effectiveness analyses on topics including but not limited to prostate cancer, bladder cancer, and geriatric-specific oncology clinics to improve outcomes. 

Clinical Value, Cost Considerations of Abiraterone Acetate, Enzalutamide in Prostate Cancer

A particular study applied the ASCO Value Framework and  European Society for Medical Oncology Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.

Read More


First-Line Docetaxel Improves QoL, Proves Cost-Effective in Prostate Cancer

The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost-effective.

Read More


Trimodal Therapy vs Radical Cystectomy for Patients With Localized Bladder Cancer

Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy vs radical cystectomy for patients with localized muscle-invasive bladder cancer.

Read More


Cost-Effectiveness of Hydrogel Rectal Spacer in Radiotherapy for Prostate Cancer

A cost-effectiveness analysis examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.

Read More


Geriatric Oncology Clinics May Help Improve Care for Patients With GU Malignancies

Another study presented at the 2018 ASCO GU Cancers Symposium evaluated the impact of a geriatric oncology clinic on cancer treatment plans and supportive care in older adults with GU cancers.

Read More


Cost-Effectiveness of Traditional Treatment vs Active Surveillance in Low-Risk Prostate Cancer

Health care costs in the United States continue to increase at a high rate, with prostate cancer expected to incur a cost of $18.53 billion in the coming years.

Read More

Back to Top